Association of Cytokine Gene Polymorphisms with Prostate Cancer Risk from a Study in Central China

Table 4

Cytokine gene polymorphisms and clinic pathological characteristics with the PCa patients in central China.

	AA	AB + BB	P value^a	Or (95% CI)	OR^b (95% CI)^b
rs16944	GG	GA + GG
Clinical
Localized	17	51	0.530	0.714 (0.250, 2.045)	0.686 (0.235, 2.002)
Advanced	7	15
Gleason
>7	11	25	0.496	1.388 (0.540, 3.568)	1.404 (0.539, 3.660)
≤7	13	41
Total PSA (ng/ml)
>20	12	27	0.442	1.444 (0.565, 3.693)	1.745 (0.654, 4.655)
≤20	12	39
rs2070874	TT	TC + CC
Clinical
Localized	40	28	0.434	0.667 (0.241, 1.847)	0.621 (0.218, 1.770)
Advanced	15	7
Gleason
>7	22	14	1.000	1.000 (0.421, 2.375)	1.075 (0.443, 2.607)
≤7	33	21
Total PSA (ng/ml)
>20	26	13	0.344	1.517 (0.638, 3.608)	1.505 (0.611, 3.707)
≤20	29	22
rs2227284	TT	TG + GG
Clinical
Localized	52	16	0.938	0.956 (0.305, 3.000)	0.873 (0.270, 2.821)
Advanced	17	5
Gleason
>7	28	8	0.839	1.110 (0.407, 3.027)	1.208 (0.431, 3.381)
≤7	41	13
Total PSA (ng/ml)
>20	31	8	0.580	1.326 (0.488, 3.605)	1.190 (0.422, 3.360)
≤20	38	13
rs7175701	TT	TC + CC
Clinical
Localized	66	2	1.000	—	—
Advanced	22	0
Gleason
>7	36	0	0.515	—	—
≤7	52	2
Total PSA (ng/ml)
>20	38	0	0.507	—	—
≤20	50	2
rs11556218	TT	TG + GG
Clinical
Localized	52	16	0.237	1.857 (0.661, 5.221)	1.876 (0.664, 5.302)
Advanced	14	8
Gleason
>7	23	13	0.098	0.453 (0.175, 1.169)	0.453 (0.174, 1.176)
≤7	43	11
Total PSA (ng/ml)
>20	29	10	0.847	1.097 (0.426, 2.826)	1.118 (0.424, 2.951)
≤20	37	14

Notes:^aTwo-sided χ2 test for the distributions between TT and TT/GG; ^badjusting for age and body mass index (BMI); ^clocalized, T1–2N0M0; advanced, T3–4NxMx or TxN1Mx or TxNxM1. Clinical staging according to the international TNM system for prostate cancer.